SC-1012 is a first-in-class oral molecule that modulates a new obesity target. It is positioned to be the next major class of obesity medicines.

Several genes with established metabolic relevance signal through this pathway with emerging evidence supporting it as a central metabolic control node.

This is the first application of this target and pathway for weight loss – opening up a new class of obesity therapeutics.

The pathway is also associated with insulin resistance, dyslipidemia, and MASH/MASLD.

SC-2004 is an oral GLP-1 receptor agonist positioned to be best in class due to its unique receptor modulation that is designed to enhance tolerability.

With current GLP-1s, ~70% of patients have significant GI side effects, including nausea and vomiting. Despite the ‘mild‑to‑moderate’ labeling, the real‑world impact is often debilitating.

60–70% of non‑diabetic patients discontinue within the first year

These effects are target‑related, not off‑target, limiting how much they can be engineered away. Strigosus’ unique approach minimizes receptor-associated side effects.